JSPR
Jasper Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$26.03M
P/E Ratio
—
EPS
$-3.95
Beta
3.20
52W High
$7.19
52W Low
$0.62
50-Day MA
$1.11
200-Day MA
$1.94
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Jasper Therapeutics Inc
Jasper Therapeutics Inc (JSPR) is an innovative biopharmaceutical firm at the forefront of hematopoietic stem cell therapy, aimed at enhancing patient outcomes for severe diseases such as sickle cell disease and targeted blood cancers. The company's pioneering approach leverages advanced technologies to minimize transplant-related risks and address critical needs in the hematology market. With a robust intellectual property portfolio and strategic partnerships, Jasper is positioned to drive its clinical pipeline forward, underscoring its commitment to transformative advancements in regenerative medicine.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-80.53M |
| Operating Margin | 0.00% |
| Return on Equity | -230.30% |
| Return on Assets | -88.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.15 |
| Price-to-Book | 6.27 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $28.00M |
| Float | $21.88M |
| % Insiders | 1.04% |
| % Institutions | 73.21% |
Historical Volatility
HV 10-Day
110.42%
HV 20-Day
135.23%
HV 30-Day
120.73%
HV 60-Day
98.39%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($7.70 target)
1
Strong Buy3
Buy3
HoldData last updated: 4/29/2026